

February 12, 2026

BSE Limited
Department of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Kala Ghoda, Fort
Mumbai 400 001
Scrip Code No: 542665
Debt Segment Code: 977028

National Stock Exchange of India Limited
Listing Department,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051
Company Symbol: NEOGEN

Sub.: Press Release on the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2025, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the captioned subject, please find enclosed herewith the Press Release on the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025.

The Press Release is also being uploaded on the Company's website at <https://neogenchem.com/financial-performance/>.

Kindly take the same on your record.

Thanking you,
For Neogen Chemicals Limited

Unnati Kanani
Company Secretary and Compliance Officer
Membership No. A35131

Encl.: As above



Q3 FY26 PRESS RELEASE

February 12, 2026

Neogen Chemicals' reports resilient performance

Revenue at INR 220 crore, higher by 9% Y-o-Y

Neogen Chemicals Limited (Neogen) reported stable financial performance for the third quarter and nine months ending 31st December, 2025. In Q3 FY26 (consolidated), revenues stood at INR 220 crore, higher by 9% YoY, driven by increased volumes in both Organic and Inorganic Chemicals supported by consistent demand. Resilient operating volumes were sustained despite Dahej capacity bottlenecks, mitigated through toll manufacturing arrangements. Neogen Ionics (NIL) Q3 FY26 revenue stood at INR 12 crore.

EBITDA for Q3 FY26 (consolidated) stood at INR 32 crore. EBITDA remained resilient on sequential basis, though Y-o-Y comparisons reflect transitory cost headwinds, like increased overheads associated with Neogen Ionics (Battery Chemicals), cost pressures from elevated insurance premiums following the fire incident, and interim toll manufacturing expenses. While some expenses will persist in the near term, eligible costs will be recovered through Loss of Profit insurance claims.

Neogen's profit after tax for Q3 FY26 (consolidated) stood at INR 4 crore. PAT was further impacted by higher finance costs linked to Dahej plant reconstruction and pre-operative and expansionary spends in Neogen Ionics.

Consolidated Earnings per share (EPS) for Q3 FY26 stood at INR 1.40 per share (not annualized).

Performance at a Glance

INR crore (Standalone)	Q3 FY26	YoY Growth
Revenues	216	↑ 8%
Gross Profit	99	↑ 8%
EBITDA	36	↓ 4%
PAT	9	↓ 39%

INR crore (Consolidated)	Q3 FY26	YoY Growth
Revenues	220	↑ 9%
Gross Profit	104	↑ 13%
EBITDA	32	↓ 8%
PAT	4	↓ 63%





Notes:

1. *Growth for Q3 FY26 is compared to Q3 FY25. And 9M FY26 is compared to 9M FY25*
2. *Profitability impacted due to post-fire operating and insurance costs; recoveries from the Loss on Profit Policy are expected in FY27*
3. *Higher interest costs for growth and plant reconstruction also impacted profitability; expected to normalize following the full insurance payout*

Commenting on the Q3 FY26 performance, Dr. Harin Kanani, Managing Director, Neogen Chemicals said:

“Our Q3 FY26 performance reflects a steady recovery and a strategic pivot toward a future-ready portfolio. In our base business, we continue to see strong resilience across non-agchem applications, specifically Pharma, F&F and more. This demand stability, combined with our product optimization initiatives and upcoming replacement plant in Dahej, ensures our core operations remain robust despite global market transitions.

In Battery Materials, we have reached a transformative phase. As several Indian gigawatt players launch capacities later this and next financial year, Neogen is positioned as the most cost-efficient lithium salt and electrolyte source with proven Japanese technologies. The non-FEOC requirement for 45X tax credit in U.S. and current substantial price increase in China remains a substantial tailwind as we expand our global footprint in lithium salt. We anticipate several large-scale customers finalizing approvals for our lithium salts, leading to bulk consignments by H1 FY27.

Operationally, the Greenfield Pakhajan Electrolyte plant is nearing mechanical completion. The specialized MUIS technology equipment has arrived at our site and assembly is currently underway. As we transition into regular, long-term supply agreements, we are confident that Neogen Ionics will become the cornerstone of our growth, reinforcing our position as a technology-led leader in the global battery chemicals value chain.”

Key Updates – Q3 FY26 (Neogen Chemicals)

- **Update on Fire Incident**
 - During the Nine month ended December 31, 2025, Company has received INR 83.48 Crore (including INR 80.00 Crore as on account payment from insurance Company), accordingly net claim receivable as on date reduced to INR 251.12 Crore
 - Construction of the replacement plant progressing rapidly, with commissioning scheduled for Q1 FY27
- **The Board has granted in-principle approval to raise up to INR 150 crore through a preferential issue of equity shares to the Promoter Group, reinforcing their commitment to the Company’s growth, subject to regulatory approvals**





UPDATE ON EXPANSION INITIATIVES

Details of expansion projects announced:	Current project updates:
Battery Chemicals Business	
New capacity of 400 MTPA for manufacturing Lithium Electrolyte Salts and Additives	<ul style="list-style-type: none"> • 200 MTPA commissioned; first approval material shipped to the customers • For remaining 200 MTPA, trial production ongoing • 1,100 MT to be commissioned by March 2026 • 1,000 MT to be commissioned by Q1 FY27
Plant for manufacturing 2,000 MT of Electrolyte at Dahej facility	<ul style="list-style-type: none"> • 2,000 MT fully commissioned

Update on Battery Chemicals (Neogen Ionics)

- **Landmark Indo-Japan Joint Venture for Electrolyte Salt Production**
 - Neogen Ionics (NII) concluded JV with Japan's Morita Investment Limited (MIL) to produce, develop, and sell solid LiPF6 salt globally
 - Neogen to hold 80% majority stake in the new entity, Neogen Morita New Materials Limited (NML), with MIL contributing \$20 million for the remaining 20%
 - The JV leverages 30+ years of globally proven Japanese technology, enhancing production efficiency and expediting access to international markets and customer approvals
 - Establishes India's only non-FEOC compliant electrolyte salt plant with proven Japanese technology, facilitating supply chain diversification from China and supporting 'Aatmanirbhar Bharat' through significant import substitution
- **Operational Update: Pakhajan Greenfield Project**
 - Commercial production of Electrolyte (H1 FY27) and Electrolyte Salt (H2 FY27) remains on track, synchronized with India's ACC battery rollout and rising global non-FEOC demand
 - Electrolyte plant and equipment arrived at Pakhajan facility; assembly underway currently; trial production expected to commence shortly thereafter
 - Successfully completed stringent PPAP and secured long-term commercial supply approval from Giga-scale Indian customer for Electrolyte; further scale-up underway
 - Received provisional approvals for Lithium Electrolyte Salts from multiple international customers; final site audits underway; completion expected by Q1 FY27

-ENDS-





About Neogen Chemicals Limited

Incorporated in 1989, Neogen Chemicals Ltd. (NSE Code: NEOGEN; BSE Code: 542665) is India's one of the leading manufacturers of Bromine-based and Lithium-based specialty chemicals.

Products

Its specialty chemicals product offerings comprise Organic as well as Inorganic chemicals. Its products are used in pharmaceutical and agrochemical intermediates, engineering fluids, electronic chemicals, polymer additives, water treatment, construction chemicals, and aroma chemicals, flavours and fragrances, specialty polymers, Chemicals and Vapour Absorption Chillers – original-equipment manufacturers and with new upcoming usage in lithium-ion battery materials for energy storage and Electric Vehicles (EV) application. Over the years, Neogen has expanded its range of products and at present, manufactures an extensive range of specialty chemicals which find application across various industries in India and the world. It has a product portfolio of over 258 products.

In addition to manufacturing specialty chemicals, Neogen also undertakes custom synthesis and contract manufacturing where the product is developed and customised primarily for a specific customer, but process know-how and technical specifications are developed in-house.

The Company has announced plans to utilise its three decades of experience in Lithium Chemistry to manufacture Lithium-Ion battery materials with an initial investment plan to manufacture electrolytes and Lithium electrolyte salts.

Facilities

The Company operates out of its four manufacturing facilities located in Mahape, Navi Mumbai in Maharashtra, Dahej SEZ, Bharuch, Karakhadi, Vadodara in Gujarat and Patancheru, Hyderabad (in January 2025, Buli Chemicals India Private Limited was merged with Neogen Chemicals, their facility was located in Patancheru).

Neogen Chemicals Limited also has a wholly owned subsidiary – Neogen Ionics Limited, dedicated to projects related to battery materials. Neogen Ionics Limited has one of the earliest LIB electrolyte facility at its Dahej SEZ site since April 2024.

For more information, please visit www.neogenchem.com OR contact:

Unnati Kanani

Neogen Chemicals Limited

Tel: +91 22 2549 7300 (Ext: 364)

Email: investor@neogenchem.com

Disclaimer: Certain statements in this press release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Neogen Chemicals Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

